You are here

Article Text

Article menu
Download PDFPDF
Treatment
Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis

https://doi.org/10.1136/ebn.8.2.49

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876–83.OpenUrlCrossRefPubMedWeb of Science

    Q What is the efficacy of fluconazole for recurrent vulvovaginal candidiasis (VC)?

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial.

    Embedded ImageAllocation:

    unclear.

    Embedded ImageBlinding:

    blinded (patients and healthcare providers).

    Embedded ImageFollow up period:

    12 months.

    Embedded ImageSetting:

    multiple centres in the US.

    Embedded ImagePatients:

    387 women ⩾18 years of age (mean age 34 y, 67% white) who had active, acute candida vaginitis (severity score ⩾3), a positive result on microscopic examination of vaginal secretions, ⩾4 episodes of candida vaginitis in the previous 12 months, and were clinically cured (severity score <3) at 14 days after receiving 3 sequential doses of fluconazole, 150 mg, at 72 hour intervals. Exclusion criteria: lack of confirmation of microscopic findings by culture, pregnancy, mixed infections or known seropositivity for HIV, or use of antifungal agents in the previous 4 weeks.

    Embedded ImageIntervention:

    a single oral dose of fluconazole, …

    View Full Text

    Footnotes

    • ↵* Data on allocation status only available for 343 women included in the efficacy analysis.

    • ↵* Calculated from data in original article.

    • For correspondence: Dr J D Sobel, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA. jsobelmed.wayne.edu

    • Source of funding: Pfizer Pharmaceutical.